ILF With/Without Cisplatin for Advanced Gastric Cancer

Sponsor: Gachon University Gil Medical Center
Study ID: NCT00320294
Phase: PHASE2
Status: Unknown

Conditions

Stomach Neoplasm

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

irinotecan — DRUG
cisplatin — DRUG

Study Details

To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.

Key Dates

Start date: Feb 28, 2005
Status verified: Mar 2007
Completion: Mar 31, 2007

Study Design

Enrollment: 86 participants
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Primary Outcome Measure

Objective response rate